NEW YORK (GenomeWeb News) – Quest announced today a definitive agreement to sell its HemoCue business to Danaher's Radiometer Medical for about $300 million.

Separately, Fitch Ratings affirmed Quest Diagnostics' Issuer Default Rating at BBB+ after the close of the market on Friday.

Based in Cypress, Calif., HemoCue develops hemoglobin, glucose, and other point-of-care testing systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.